DeepMed Research

Riluzole

Generic Name: Riluzole

Brand Names: Exservan, Rilutek, Tiglutik, Riluzole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₅F_₃N_₂OS

CAS Number: 1744-22-5

Unique Ingredient Identifier: 7LJ087RS6F

Background: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication: For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions: Amyotrophic Lateral Sclerosis (ALS)

Clinical Trials

Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis

Early Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Riluzole
Biological: Plasma from healthy young people treatment + Riluzole

First Posted Date: 2020-07-02

Last Posted Date: 2020-07-07

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 20

Registration Number: NCT04454840

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 1

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Trametinib (0.5 mg)
Drug: Trametinib (1 mg)
Drug: Riluzole (100 mg)

First Posted Date: 2020-03-30

Last Posted Date: 2023-05-09

Lead Sponsor: Genuv Inc.

Target Recruit Count: 23

Registration Number: NCT04326283

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

and more 2 locations

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

Phase 2

Suspended

Conditions: Oxaliplatin-induced Peripheral Neuropathy

Interventions: Drug: Placebo Oral Tablet
Drug: Riluzole

First Posted Date: 2018-10-29

Last Posted Date: 2025-04-23

Lead Sponsor: UNICANCER

Target Recruit Count: 80

Registration Number: NCT03722680

Locations: 🇫🇷
CHU de Clermont -Ferrand, Clermont-Ferrand, France
🇫🇷
ICO - Site Paul Papin, Angers, France
🇫🇷
CH Beauvais, Beauvais, France

and more 13 locations

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Riluzole Oral Soluble film (ROSF) 50 mg

First Posted Date: 2018-09-21

Last Posted Date: 2020-08-18

Lead Sponsor: Aquestive Therapeutics

Target Recruit Count: 9

Registration Number: NCT03679975

Locations: 🇺🇸
University of Florida Center for Movement Disorders & Neuroscience, Gainesville, Florida, United States

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Phase 2

Recruiting

Conditions: SCA7

Interventions: Drug: Riluzole
Drug: Placebo

First Posted Date: 2018-09-07

Last Posted Date: 2024-12-02

Lead Sponsor: S. Andrea Hospital

Target Recruit Count: 34

Registration Number: NCT03660917

Locations: 🇮🇹
Neurological Unit, S. Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy

Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)

Conditions: ALS
Amyotrophic Lateral Sclerosis
Lou Gehrig Disease
Lou Gehrig's Disease
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Lou-Gehrigs Disease

First Posted Date: 2018-05-25

Last Posted Date: 2019-07-26

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Registration Number: NCT03537807

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

Phase 1

Completed

Conditions: Lou Gehrig's Disease
Amyotrophic Lateral Sclerosis
ALS
Lou Gehrig Disease
Lou-Gehrigs Disease
Motor Neuron Disease, Amyotrophic Lateral Sclerosis

Interventions: Drug: BHV-0223

First Posted Date: 2018-05-09

Last Posted Date: 2022-10-06

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 22

Registration Number: NCT03520517

Locations: 🇺🇸
Wesley Neurology Clinic, Cordova, Tennessee, United States
🇺🇸
Holy Cross Neuroscience Research Institute, Fort Lauderdale, Florida, United States
🇺🇸
Texas Neurology, Dallas, Texas, United States

and more 2 locations

Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis

Phase 2

Withdrawn

Conditions: ALS

Interventions: Drug: Riluzole Oral Soluble Film

First Posted Date: 2018-03-08

Last Posted Date: 2019-05-13

Lead Sponsor: Aquestive Therapeutics

Registration Number: NCT03457753

Locations: 🇺🇸
Texas Neurology, P.A., Dallas, Texas, United States

Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)

Phase 3

Completed

Conditions: Spinocerebellar Ataxia Type 2

Interventions: Drug: Riluzole
Drug: Placebo

First Posted Date: 2017-11-20

Last Posted Date: 2021-06-21

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 42

Registration Number: NCT03347344

Locations: 🇫🇷
Durr, Paris, France

Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Conditions: Neuromuscular Diseases

Interventions: Drug: Edaravone
Drug: Riluzole

First Posted Date: 2017-09-06

Last Posted Date: 2019-03-27

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT03272802

Locations: 🇮🇷
EMG Department, Alzahra Hospital, Isfahan, Iran, Islamic Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy